Viscoelastic and ultrastructural characteristics of whole blood and plasma in Alzheimer-type dementia, and the possible role of bacterial lipopolysaccharides (LPS)

Oncotarget

Volumn 6, Issue 34, 2015, Pages 35284-35303

  Bester, Janette ^a   Soma, Prashilla ^a   Kell, Douglas B ^b   Pretorius, Etheresia ^a  

^a UNIVERSITY OF PRETORIA   (South Africa)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

Author keywords

Alzheimer type dementia; Gerotarget; Iron levels; Lipopolysaccharides; Scanning electron microscopy; Thromboelastography

Indexed keywords

BACTERIUM LIPOPOLYSACCHARIDE; ENDOTOXIN; IRON; LIPOPOLYSACCHARIDE; VISCOELASTIC SUBSTANCE;

AGED; ALZHEIMER DISEASE; ARTICLE; BACTERIAL CELL WALL; BACTERIAL STRAIN; BLOOD ANALYSIS; CELL COMPONENT; CELL STRUCTURE; CONTROLLED STUDY; ERYTHROCYTE; ESCHERICHIA COLI; FEMALE; GLOBAL THROMBOSIS TEST; HEMATOLOGICAL PROCEDURE; HUMAN; HUMAN CELL; HYPERCOAGULABILITY; MALE; MICROBIOME; PLASMA CELL; SCANNING ELECTRON MICROSCOPY; STRUCTURE ANALYSIS; THROMBOCYTE FUNCTION; THROMBOCYTE POOR PLASMA; THROMBOELASTOGRAPHY; VISCOELASTICITY; BLOOD; METABOLISM; PROCEDURES;

ALZHEIMER DISEASE; HUMANS; IRON; LIPOPOLYSACCHARIDES; MICROSCOPY, ELECTRON, SCANNING; THROMBELASTOGRAPHY; VISCOELASTIC SUBSTANCES;

EID: 84946865861     PISSN: None     EISSN: 19492553     Source Type: Journal    
DOI: 10.18632/oncotarget.6074     Document Type: Article

References (184)

1. Meraz-Rios MA, Toral-Rios D, Franco-Bocanegra D, Villeda-Hernandez J and Campos-Pena V. Inflammatory process in Alzheimer's Disease. Frontiers in integrative neuroscience. 2013; 7:59.
2. Zou Z, Liu C, Che C and Huang H. Clinical genetics of Alzheimer's disease. BioMed research international. 2014; 2014:291862.
3. Kim DH, Yeo SH, Park JM, Choi JY, Lee TH, Park SY, Ock MS, Eo J, Kim HS and Cha HJ. Genetic markers for diagnosis and pathogenesis of Alzheimer's disease. Gene. 2014; 545(2):185-193.
4. Morris JK, Honea RA, Vidoni ED, Swerdlow RH and Burns JM. Is Alzheimer's disease a systemic disease? Biochimica et biophysica acta. 2014; 1842(9):1340-1349.
5. Skaper SD. Alzheimer's disease and amyloid: culprit or coincidence? International review of neurobiology. 2012; 102:277-316.
6. Fargo KN, Aisen P, Albert M, Au R, Corrada MM, DeKosky S, Drachman D, Fillit H, Gitlin L, Haas M, Herrup K, Kawas C, Khachaturian AS, Khachaturian ZS, Klunk W, Knopman D, et al. 2014 Report on the Milestones for the US National Plan to Address Alzheimer's Disease. Alzheimer's & dementia: the journal of the Alzheimer's Association. 2014; 10(5 Suppl):S430-452.
7. Association. As. 2015 Alzheimer's disease facts and figures. Alzheimer's & dementia: the journal of the Alzheimer's Association. 2015; 11(3):332-384.
8. Thériault P, ElAli A and Rivest S. The dynamics of monocytes and microglia in Alzheimer's disease. Alzheimer's research & therapy. 2015; 7(1):41.
9. ElAli A and Rivest S. Microglia in Alzheimer's disease: A multifaceted relationship. Brain, behavior, and immunity. 2015.
10. Steardo L Jr., Bronzuoli MR, Iacomino A, Esposito G, Steardo L and Scuderi C. Does neuroinflammation turn on the flame in Alzheimer's disease? Focus on astrocytes. Frontiers in neuroscience. 2015; 9:259.
11. Ben Haim L, Carrillo-de Sauvage MA, Ceyzériat K and Escartin C. Elusive roles for reactive astrocytes in neurodegenerative diseases. Frontiers in cellular neuroscience. 2015; 9:278.
12. von Bernhardi R, Eugenín-von Bernhardi L and Eugenín J. Microglial cell dysregulation in brain aging and neurodegeneration. Frontiers in aging neuroscience. 2015; 7:124.
13. Wang WY, Tan MS, Yu JT and Tan L. Role of proinflammatory cytokines released from microglia in Alzheimer's disease. Annals of translational medicine. 2015; 3(10):136.
14. Denes A, Thornton P, Rothwell NJ and Allan SM. Inflammation and brain injury: acute cerebral ischaemia, peripheral and central inflammation. Brain, behavior, and immunity. 2010; 24(5):708-723.
15. Drake C, Boutin H, Jones MS, Denes A, McColl BW, Selvarajah JR, Hulme S, Georgiou RF, Hinz R, Gerhard A, Vail A, Prenant C, Julyan P, Maroy R, Brown G, Smigova A, et al. Brain inflammation is induced by co-morbidities and risk factors for stroke. Brain, behavior, and immunity. 2011; 25(6):1113-1122.
16. Kell DB, Potgieter M and Pretorius E. Individuality, phenotypic differentiation, dormancy and 'persistence' in culturable bacterial systems: commonalities in environmental, laboratory, and clinical microbiology. F1000Review. 2015; In Press.
17. Kell DB and Pretorius E. On the translocation of bacteria and their lipopolysaccharides between blood and peripheral locations in chronic, inflammatory diseases: the central roles of LPS and LPS-induced cell death. Integrative Biology. 2015; online, DOI: 10.1039/c5ib00158g.
18. Kamat PK, Vacek JC, Kalani A and Tyagi N. Homocysteine Induced Cerebrovascular Dysfunction: A Link to Alzheimer's Disease Etiology. The open neurology journal. 2015; 9:9-14.
19. Jansen WJ, Ossenkoppele R, Knol DL, Tijms BM, Scheltens P, Verhey FR, Visser PJ, Aalten P, Aarsland D, Alcolea D, Alexander M, Almdahl IS, Arnold SE, Baldeiras I, Barthel H, van Berckel BN, et al. Prevalence of cerebral amyloid pathology in persons without dementia: a meta-analysis. JAMA: the journal of the American Medical Association. 2015; 313(19):1924-1938.
20. Reitz C. Alzheimer's disease and the amyloid cascade hypothesis: a critical review. International journal of Alzheimer's disease. 2012; 2012:369808.
21. Tang Z, Ioja E, Bereczki E, Hultenby K, Li C, Guan Z, Winblad B and Pei JJ. mTor mediates tau localization and secretion: implication for Alzheimer's disease. Biochimica et biophysica acta. 2015.
22. Zhu S, Shala A, Bezginov A, Sljoka A, Audette G and Wilson DJ. Hyperphosphorylation of intrinsically disordered tau protein induces an amyloidogenic shift in its conformational ensemble. PLoS One. 2015; 10(3):e0120416.
23. Pimplikar SW. Reassessing the amyloid cascade hypothesis of Alzheimer's disease. The international journal of biochemistry & cell biology. 2009; 41(6):1261-1268.
24. Herrup K. The case for rejecting the amyloid cascade hypothesis. Nature neuroscience. 2015; 18(6):794-799.
25. Rubio-Perez JM and Morillas-Ruiz JM. A review: inflammatory process in Alzheimer's disease, role of cytokines. TheScientificWorldJournal. 2012; 2012:756357.
26. Doens D and Fernández PL. Microglia receptors and their implications in the response to amyloid beta for Alzheimer's disease pathogenesis. Journal of neuroinflammation. 2014; 11:48.
27. McGeer PL and McGeer EG. Innate immunity, local inflammation, and degenerative disease. Science of aging knowledge environment: SAGE KE. 2002; 2002(29):re3.
28. Heneka MT, Carson MJ, Khoury JE, Landreth GE, Brosseron F, Feinstein DL, Jacobs AH, Wyss-Coray T, Vitorica J, Ransohoff RM, Herrup K, Frautschy SA, Finsen B, Brown GC, Verkhratsky A, Yamanaka K, et al. Neuroinflammation in Alzheimer's disease. Lancet neurology. 2015; 14(4):388-405.
29. Ong WY and Farooqui AA. Iron, neuroinflammation, and Alzheimer's disease. Journal of Alzheimer's disease: JAD. 2005; 8(2):183-200; discussion 209-115.
30. Tuppo EE and Arias HR. The role of inflammation in Alzheimer's disease. The international journal of biochemistry & cell biology. 2005; 37(2):289-305.
31. Tzeng SF, Hsiao HY and Mak OT. Prostaglandins and cyclooxygenases in glial cells during brain inflammation. Current drug targets Inflammation and allergy. 2005; 4(3):335-340.
32. Varley J, Brooks DJ and Edison P. Imaging neuroinflammation in Alzheimer's and other dementias: Recent advances and future directions. Alzheimer's & dementia: the journal of the Alzheimer's Association. 2014.
33. Latta CH, Brothers HM and Wilcock DM. Neuroinflammation in Alzheimer's disease; A source of heterogeneity and target for personalized therapy. Neuroscience. 2014.
34. Castellani RJ, Moreira PI, Perry G and Zhu X. The role of iron as a mediator of oxidative stress in Alzheimer disease. BioFactors (Oxford, England). 2012; 38(2):133-138.
35. Connor JR, Menzies SL, St Martin SM and Mufson EJ. A histochemical study of iron, transferrin, and ferritin in Alzheimer's diseased brains. Journal of neuroscience research. 1992; 31(1):75-83.
36. Crichton RR, Dexter DT and Ward RJ. Brain iron metabolism and its perturbation in neurological diseases. Journal of neural transmission (Vienna, Austria: 1996). 2011; 118(3):301-314.
37. Friedman A, Arosio P, Finazzi D, Koziorowski D and Galazka-Friedman J. Ferritin as an important player in neurodegeneration. Parkinsonism & related disorders. 2011; 17(6):423-430.
38. Kell DB. Iron behaving badly: inappropriate iron chelation as a major contributor to the aetiology of vascular and other progressive inflammatory and degenerative diseases. BMC medical genomics. 2009; 2:2.
39. Kell DB. Towards a unifying, systems biology understanding of large-scale cellular death and destruction caused by poorly liganded iron: Parkinson's, Huntington's, Alzheimer's, prions, bactericides, chemical toxicology and others as examples. Archives of toxicology. 2010; 84(11):825-889.
40. Smith MA, Zhu X, Tabaton M, Liu G, McKeel DW, Jr., Cohen ML, Wang X, Siedlak SL, Dwyer BE, Hayashi T, Nakamura M, Nunomura A and Perry G. Increased iron and free radical generation in preclinical Alzheimer disease and mild cognitive impairment. Journal of Alzheimer's disease: JAD. 2010; 19(1):363-372.
41. Wood H. Alzheimer disease: Iron-the missing link between ApoE and Alzheimer disease? Nature reviews Neurology. 2015; 11(7):369.
42. Ayton S and Faux NG. Ferritin levels in the cerebrospinal fluid predict Alzheimer's disease outcomes and are regulated by APOE. 2015; 6:6760.
43. Yang H, Guan H, Yang M, Liu Z, Takeuchi S, Yanagisawa D, Vincent SR, Zhao S and Tooyama I. Upregulation of mitochondrial ferritin by proinflammatory cytokines: implications for a role in Alzheimer's disease. Journal of Alzheimer's disease: JAD. 2015; 45(3):797-811.
44. Bandyopadhyay S and Rogers JT. Alzheimer's disease therapeutics targeted to the control of amyloid precursor protein translation: maintenance of brain iron homeostasis. Biochemical pharmacology. 2014; 88(4):486-494.
45. Crespo âC, Silva B, Marques L, Marcelino E, Maruta C, Costa S, Timóteo A, Vilares A, Couto FS, Faustino P, Correia AP, Verdelho A, Porto G, Guerreiro M, Herrero A, Costa C, et al. Genetic and biochemical markers in patients with Alzheimer's disease support a concerted systemic iron homeostasis dysregulation. Neurobiology of aging. 2014; 35(4):777-785.
46. Hadzhieva M, Kirches E and Mawrin C. Review: iron metabolism and the role of iron in neurodegenerative disorders. Neuropathology and applied neurobiology. 2014; 40(3):240-257.
47. Ward RJ, Dexter DT and Crichton RR. Neurodegenerative diseases and therapeutic strategies using iron chelators. Journal of trace elements in medicine and biology: organ of the Society for Minerals and Trace Elements (GMS). 2015; 31:267-273.
48. Collingwood JF and Davidson MR. The role of iron in neurodegenerative disorders: insights and opportunities with synchrotron light. Frontiers in pharmacology. 2014; 5:191.
49. Casadesus G, Smith MA, Zhu X, Aliev G, Cash AD, Honda K, Petersen RB and Perry G. Alzheimer disease: evidence for a central pathogenic role of iron-mediated reactive oxygen species. Journal of Alzheimer's disease: JAD. 2004; 6(2):165-169.
50. Crapper McLachlan DR, Dalton AJ, Kruck TP, Bell MY, Smith WL, Kalow W and Andrews DF. Intramuscular desferrioxamine in patients with Alzheimer's disease. Lancet. 1991; 337(8753):1304-1308.
51. Pretorius E, Bester J, Vermeulen N and Lipinski B. Oxidation inhibits iron-induced blood coagulation. Current drug targets. 2013; 14(1):13-19.
52. Pretorius E, Bester J, Vermeulen N, Lipinski B, Gericke GS and Kell DB. Profound morphological changes in the erythrocytes and fibrin networks of patients with hemochromatosis or with hyperferritinemia, and their normalization by iron chelators and other agents. PlosOne. 2014; doi: 10.1371/journal.pone.0085271. eCollection 2014.
53. Pretorius E and Kell DB. Diagnostic morphology: biophysical indicators for iron-driven inflammatory diseases. Integrative Biology. 2014; 6:486-510.
54. Pretorius E and Lipinski B. Differences in Morphology of Fibrin Clots Induced with Thrombin and Ferric Ions and Its Pathophysiological Consequences. Heart, lung & circulation. 2012; 22:447-449.
55. Pretorius E, Vermeulen N, Bester J, Lipinski B and Kell DB. A novel method for assessing the role of iron and its functional chelation in fibrin fibril formation: the use of scanning electron microscopy. Toxicology mechanisms and methods. 2013; 23(5):352-359.
56. Undas A and Ariëns RAS. Fibrin clot structure and function: a role in the pathophysiology of arterial and venous thromboembolic diseases. Arterioscler Thromb Vasc Biol. 2011; 31(12):e88-99.
57. Kell DB and Pretorius E. Serum ferritin is an important inflammatory disease marker, as it is mainly a leakage product from damaged cells. Metallomics. 2014; 4:748-773.
58. Kell DB and Pretorius E. The simultaneous occurrence of both hypercoagulability and hypofibrinolysis in blood and serum during systemic inflammation, and the roles of iron and fibrin(ogen). Integrative Biology. 2015; 7:24-52.
59. Dávalos D and Akassoglou K. Fibrinogen as a key regulator of inflammation in disease. Semin Immunopathol. 2012; 34(1):43-62.
60. Duvoix A, Dickens J, Haq I, Mannino D, Miller B, TalSinger R and Lomas DA. Blood fibrinogen as a biomarker of chronic obstructive pulmonary disease. Thorax. 2013; 68(7):670-676.
61. Erikssen G, Liestol K, Bjornholt JV, Stormorken H, Thaulow E and Erikssen J. Erythrocyte sedimentation rate: a possible marker of atherosclerosis and a strong predictor of coronary heart disease mortality. European heart journal. 2000; 21(19):1614-1620.
62. Fries D and Martini WZ. Role of fibrinogen in traumainduced coagulopathy. British journal of anaesthesia. 2010; 105(2):116-121.
63. Késmárky G, Kenyeres P, Késmárky M and Tóth K. Plasma viscosity: a forgotten variable. Clinical hemorheology and microcirculation. 2008; 39(1-4):243-246.
64. Kolodziejczyk J and Ponczek MB. The role of fibrinogen, fibrin and fibrin(ogen) degradation products (FDPs) in tumor progression. Contemporary oncology (Poznan, Poland). 2013; 17(2):113-119.
65. Pulanic D and Rudan I. The past decade: fibrinogen. Collegium antropologicum. 2005; 29(1):341-349.
66. Cortes-Canteli M, Paul J, Norris EH, Bronstein R, Ahn HJ, Zamolodchikov D, Bhuvanendran S, Fenz KM and Strickland S. Fibrinogen and beta-amyloid association alters thrombosis and fibrinolysis: a possible contributing factor to Alzheimer's disease. Neuron. 2010; 66(5):695-709.
67. Narayan PJ, Kim SL, Lill C, Feng S, Faull RL, Curtis MA and Dragunow M. Assessing fibrinogen extravasation into Alzheimer's disease brain using high-content screening of brain tissue microarrays. Journal of neuroscience methods. 2015; 247:41-49.
68. Cortes-Canteli M, Mattei L, Richards AT, Norris EH and Strickland S. Fibrin deposited in the Alzheimer's disease brain promotes neuronal degeneration. Neurobiology of aging. 2015; 36(2):608-617.
69. Ahn HJ, Glickman JF, Poon KL, Zamolodchikov D, JnoCharles OC, Norris EH and Strickland S. A novel Abetafibrinogen interaction inhibitor rescues altered thrombosis and cognitive decline in Alzheimer's disease mice. J Exp Med. 2014; 211(6):1049-1062.
70. Walton BL, Byrnes JR and Wolberg AS. Fibrinogen, red blood cells, and factor XIII in venous thrombosis. Journal of thrombosis and haemostasis: JTH. 2015; 13 Suppl 1:S208-215.
71. Ma X, Ji XM, Fu P, Ding YC, Xue Q and Huang Y. Coexistence of High Fibrinogen and Low High-density Lipoprotein Cholesterol Levels Predicts Recurrent Cerebral Venous Thrombosis. Chinese medical journal. 2015; 128(13):1732-1737.
72. Ahmed MS, Jadhav AB, Hassan A and Meng QH. Acute Phase Reactants as Novel Predictors of Cardiovascular Disease. ISRN inflammation. 2012; 2012:953461.
73. Ariëns RAS. Fibrin(ogen) and thrombotic disease. J Thromb Haemost. 2013; 11 Suppl 1:294-305.
74. Barr JD, Chauhan AK, Schaeffer GV, Hansen JK and Motto DG. Red blood cells mediate the onset of thrombosis in the ferric chloride murine model. Blood. 2013; 121(18):3733-3741.
75. Day SM, Duquaine D, Mundada LV, Menon RG, Khan BV, Rajagopalan S and Fay WP. Chronic iron administration increases vascular oxidative stress and accelerates arterial thrombosis. Circulation. 2003; 107(20):2601-2606.
76. Franchini M, Targher G, Montagnana M and Lippi G. Iron and thrombosis. Annals of hematology. 2008; 87(3):167-173.
77. Lipinski B and Pretorius E. Iron-Induced Fibrin in Cardiovascular Disease. Current neurovascular research. 2013.
78. Lipinski B, Pretorius E, Oberholzer HM and van der Spuy WJ. Interaction of fibrin with red blood cells: the role of iron. Ultrastruct Pathol. 2012; 36(2):79-84.
79. Nielsen VG and Pretorius E. Iron-enhanced coagulation is attenuated by chelation A thrombelastographic and ultrastructural analysis. Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis. 2014; 25(8):845-850.
80. Singh N, Haldar S, Tripathi AK, McElwee MK, Horback K and Beserra A. Iron in Neurodegenerative Disorders of Protein Misfolding: A Case of Prion Disorders and Parkinson's Disease. Antioxidants & redox signaling. 2014.
81. Pretorius E, Oberholzer HM, van der Spuy WJ and Meiring JH. Smoking and coagulation: the sticky fibrin phenomenon. Ultrastruct Pathol. 2010; 34(4):236-239.
82. Pretorius E, Oberholzer HM, van der Spuy WJ, Swanepoel AC and Soma P. Scanning electron microscopy of fibrin networks in rheumatoid arthritis: a qualitative analysis. Rheumatology international. 2012; 32(6):1611-1615.
83. Pretorius E, Swanepoel AC, Oberholzer HM, Van Der Spuy WJ, Duim W and Wessels PF. A descriptive investigation of the ultrastructure of fibrin networks in thrombo-embolic ischemic stroke. Journal of thrombosis and thrombolysis. 2011; 31(4):507-513.
84. Pretorius E, Vermeulen N, Bester J and Lipinski B. Novel use of scanning electron microscopy for detection of ironinduced morphological changes in human blood. Microsc Res Tech. 2013; 76(3):268-271.
85. Swanepoel AC, Nielsen VG and Pretorius E. Viscoelasticity and Ultrastructure in Coagulation and Inflammation: Two Diverse Techniques, One Conclusion. Inflammation eprint (ahead of print). 2015.
86. van Rooy M, Duim W, Ehlers R, Buys AV and Pretorius E. Platelet hyperactivity and fibrin clot structure in metabolic syndrome-induced transient ischemic attack: a microscopy and thromboelastography® study. Cardiovascular diabetology. 2015; Accepted.
87. Nielsen VG and Pretorius E. Iron and carbon monoxide enhance coagulation and attenuate fibrinolysis by different mechanisms. Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis. 2014; 25(7):695-702.
88. Nielsen VG, Pretorius E, Bester J, Jacobsen WK, Boyle PK and Reinhard JP. Carbon monoxide and iron modulate plasmatic coagulation in Alzheimer's disease. Current neurovascular research. 2015; 12(1):31-39.
89. Lipinski B and Pretorius E. Novel pathway of iron-induced blood coagulation: implications for diabetes mellitus and its complications. Polskie Archiwum Medycyny Wewnetrznej. 2012; 122(3):115-122.
90. Potgieter M, Bester J, Kell DB and Pretorius E. The dormant blood microbiome in chronic, inflammatory diseases. FEMS microbiology reviews. 2015:pii: fuv013.
91. Kaprelyants AS, Gottschal JC and Kell DB. Dormancy in non-sporulating bacteria. FEMS microbiology reviews. 1993; 10(3-4):271-285.
92. Kell DB, Kaprelyants AS, Weichart DH, Harwood CR and Barer MR. Viability and activity in readily culturable bacteria: a review and discussion of the practical issues. Antonie van Leeuwenhoek. 1998; 73(2):169-187.
93. Shaik MM, Ahmad S, Gan SH, Abuzenadah AM, Ahmad E, Tabrez S, Ahmed F and Kamal MA. How do periodontal infections affect the onset and progression of Alzheimer's disease? CNS & neurological disorders drug targets. 2014; 13(3):460-466.
94. Honjo K, van Reekum R and Verhoeff NP. Alzheimer's disease and infection: do infectious agents contribute to progression of Alzheimer's disease? Alzheimer's & dementia: the journal of the Alzheimer's Association. 2009; 5(4):348-360.
95. de Souza Rolim T, Fabri GM, Nitrini R, Anghinah R, Teixeira MJ, de Siqueira JT, Cestari JA and de Siqueira SR. Oral infections and orofacial pain in Alzheimer's disease: a case-control study. Journal of Alzheimer's disease: JAD. 2014; 38(4):823-829.
96. Miklossy J. Alzheimer's disease-a neurospirochetosis. Analysis of the evidence following Koch's and Hill's criteria. Journal of neuroinflammation. 2011; 8:90.
97. Itzhaki RF. Herpes simplex virus type 1 and Alzheimer's disease: increasing evidence for a major role of the virus. Frontiers in aging neuroscience. 2014; 6:202.
98. Hill JM, Bhattacharjee S, Pogue AI and Lukiw WJ. The gastrointestinal tract microbiome and potential link to Alzheimer's disease. Frontiers in neurology. 2014; 5:43.
99. Hill JM, Clement C, Pogue AI, Bhattacharjee S, Zhao Y and Lukiw WJ. Pathogenic microbes, the microbiome, and Alzheimer's disease (AD). Frontiers in aging neuroscience. 2014; 6:127.
100. Hill JM and Lukiw WJ. Microbial-generated amyloids and Alzheimer's disease (AD). Frontiers in aging neuroscience. 2015; 7:9.
101. Kamer AR, Dasanayake AP, Craig RG, Glodzik-Sobanska L, Bry M and de Leon MJ. Alzheimer's disease and peripheral infections: the possible contribution from periodontal infections, model and hypothesis. Journal of Alzheimer's disease: JAD. 2008; 13(4):437-449.
102. Gaur S and Agnihotri R. Alzheimer's disease and chronic periodontitis: Is there an association? Geriatrics & gerontology international. 2014.
103. Farhad SZ, Amini S, Khalilian A, Barekatain M, Mafi M, Barekatain M and Rafei E. The effect of chronic periodontitis on serum levels of tumor necrosis factoralpha in Alzheimer disease. Dental research journal. 2014; 11(5):549-552.
104. Sparks Stein P, Steffen MJ, Smith C, Jicha G, Ebersole JL, Abner E and Dawson D, 3rd. Serum antibodies to periodontal pathogens are a risk factor for Alzheimer's disease. Alzheimer's & dementia: the journal of the Alzheimer's Association. 2012; 8(3):196-203.
105. Kamer AR, Craig RG, Dasanayake AP, Brys M, GlodzikSobanska L and de Leon MJ. Inflammation and Alzheimer's disease: possible role of periodontal diseases. Alzheimer's & dementia: the journal of the Alzheimer's Association. 2008; 4(4):242-250.
106. Singhrao SK, Harding A, Simmons T, Robinson S, Kesavalu L and Crean S. Oral inflammation, tooth loss, risk factors, and association with progression of Alzheimer's disease. Journal of Alzheimer's disease: JAD. 2014; 42(3):723-737.
107. Poole S, Singhrao SK, Kesavalu L, Curtis MA and Crean S. Determining the presence of periodontopathic virulence factors in short-term postmortem Alzheimer's disease brain tissue. Journal of Alzheimer's disease: JAD. 2013; 36(4):665-677.
108. Miklossy J. Historic evidence to support a causal relationship between spirochetal infections and Alzheimer's disease. Frontiers in aging neuroscience. 2015; 7:46.
109. Ransmayr GN, Holliger S, Schletterer K, Heidler H, Deibl M, Poewe W, Madersbacher H and Kiss G. Lower urinary tract symptoms in dementia with Lewy bodies, Parkinson disease, and Alzheimer disease. Neurology. 2008; 70(4):299-303.
110. Eriksson I, Gustafson Y, Fagerstrom L and Olofsson B. Urinary tract infection in very old women is associated with delirium. International psychogeriatrics/IPA. 2011; 23(3):496-502.
111. Ogama N, Yoshida M, Nakai T, Niida S, Toba K and Sakurai T. Frontal white matter hyperintensity predicts lower urinary tract dysfunction in older adults with amnestic mild cognitive impairment and Alzheimer's disease. Geriatrics & gerontology international. 2015.
112. Asti A and Gioglio L. Can a bacterial endotoxin be a key factor in the kinetics of amyloid fibril formation? Journal of Alzheimer's disease: JAD. 2014; 39(1):169-179.
113. Kanekiyo T, Xu H and Bu G. ApoE and Abeta in Alzheimer's disease: accidental encounters or partners? Neuron. 2014; 81(4):740-754.
114. Schmidt V, Carlo AS and Willnow TE. Apolipoprotein E receptor pathways in Alzheimer disease. Wiley interdisciplinary reviews Systems biology and medicine. 2014; 6(3):255-270.
115. Wang C, Yu JT, Wang HF, Jiang T, Tan CC, Meng XF, Soares HD and Tan L. Meta-analysis of peripheral blood apolipoprotein E levels in Alzheimer's disease. PLoS One. 2014; 9(2):e89041.
116. Šerỳ O, Hlinecká L, Balcar VJ, Janout V and Povova J. Diabetes, hypertension and stroke-does Alzheimer protect you? Neuro endocrinology letters. 2015; 35(8):691-696.
117. Rodriguez GA, Tai LM, LaDu MJ and Rebeck GW. Human APOE4 increases microglia reactivity at Abeta plaques in a mouse model of Abeta deposition. Journal of neuroinflammation. 2014; 11:111.
118. Saura J, Petegnief V, Wu X, Liang Y and Paul SM. Microglial apolipoprotein E and astroglial apolipoprotein J expression in vitro: opposite effects of lipopolysaccharide. Journal of neurochemistry. 2003; 85(6):1455-1467.
119. Cunningham C, Wilcockson DC, Campion S, Lunnon K and Perry VH. Central and systemic endotoxin challenges exacerbate the local inflammatory response and increase neuronal death during chronic neurodegeneration. The Journal of neuroscience: the official journal of the Society for Neuroscience. 2005; 25(40):9275-9284.
120. Lee JW, Lee YK, Yuk DY, Choi DY, Ban SB, Oh KW and Hong JT. Neuro-inflammation induced by lipopolysaccharide causes cognitive impairment through enhancement of beta-amyloid generation. Journal of neuroinflammation. 2008; 5:37.
121. Herrera AJ, Tomás-Camardiel M, Venero JL, Cano J and Machado A. Inflammatory process as a determinant factor for the degeneration of substantia nigra dopaminergic neurons. Journal of neural transmission (Vienna, Austria: 1996). 2005; 112(1):111-119.
122. De Pablos RM, Herrera AJ, Villaran RF, Cano J and Machado A. Dopamine-dependent neurotoxicity of lipopolysaccharide in substantia nigra. FASEB journal: official publication of the Federation of American Societies for Experimental Biology. 2005; 19(3):407-409.
123. Byler SL, Boehm GW, Karp JD, Kohman RA, Tarr AJ, Schallert T and Barth TM. Systemic lipopolysaccharide plus MPTP as a model of dopamine loss and gait instability in C57Bl/6J mice. Behav Brain Res. 2009; 198(2):434-439.
124. Kelly LP, Carvey PM, Keshavarzian A, Shannon KM, Shaikh M, Bakay RA and Kordower JH. Progression of intestinal permeability changes and alpha-synuclein expression in a mouse model of Parkinson's disease. Movement disorders: official journal of the Movement Disorder Society. 2014; 29(8):999-1009.
125. Hoban DB, Connaughton E, Connaughton C, Hogan G, Thornton C, Mulcahy P, Moloney TC and Dowd E. Further characterisation of the LPS model of Parkinson's disease: a comparison of intra-nigral and intra-striatal lipopolysaccharide administration on motor function, microgliosis and nigrostriatal neurodegeneration in the rat. Brain, behavior, and immunity. 2013; 27(1):91-100.
126. Hritcu L and Ciobica A. Intranigral lipopolysaccharide administration induced behavioral deficits and oxidative stress damage in laboratory rats: relevance for Parkinson's disease. Behav Brain Res. 2013; 253:25-31.
127. Hritcu L, Ciobica A, Stefan M, Mihasan M, Palamiuc L and Nabeshima T. Spatial memory deficits and oxidative stress damage following exposure to lipopolysaccharide in a rodent model of Parkinson's disease. Neuroscience research. 2011; 71(1):35-43.
128. Tufekci KU, Genc S and Genc K. The endotoxininduced neuroinflammation model of Parkinson's disease. Parkinson's disease. 2011; 2011:487450.
129. Zhan X, Cox C, Ander BP, Liu D, Stamova B, Jin LW, Jickling GC and Sharp FR. Inflammation Combined with Ischemia Produces Myelin Injury and Plaque-Like Aggregates of Myelin, Amyloid-beta and AbetaPP in Adult Rat Brain. Journal of Alzheimer's disease: JAD. 2015.
130. Deng X, Li M, Ai W, He L, Lu D, Patrylo PR, Cai H, Luo X, Li Z and Yan X. Lipolysaccharide-Induced Neuroinflammation Is Associated with AlzheimerLike Amyloidogenic Axonal Pathology and Dendritic Degeneration in Rats. Advances in Alzheimer's disease. 2014; 3(2):78-93.
131. Xu Z, Wu J, Zheng J, Ma H, Zhang H, Zhen X, Zheng LT and Zhang X. Design, synthesis and evaluation of a series of non-steroidal anti-inflammatory drug conjugates as novel neuroinflammatory inhibitors. International immunopharmacology. 2015; 25(2):528-537.
132. de Punder K and Pruimboom L. Stress induces endotoxemia and low-grade inflammation by increasing barrier permeability. Frontiers in immunology. 2015; 6:223.
133. Zhang XY, Cao JB, Zhang LM, Li YF and Mi WD. Deferoxamine attenuates lipopolysaccharide-induced neuroinflammation and memory impairment in mice. Journal of neuroinflammation. 2015; 12(1):20.
134. Daulatzai MA. Role of stress, depression, and aging in cognitive decline and Alzheimer's disease. Current topics in behavioral neurosciences. 2014; 18:265-296.
135. Jain NK, Patil CS, Kulkarni SK and Singh A. Modulatory role of cyclooxygenase inhibitors in aging-and scopolamine or lipopolysaccharide-induced cognitive dysfunction in mice. Behav Brain Res. 2002; 133(2):369-376.
136. Davis DH, Skelly DT, Murray C, Hennessy E, Bowen J, Norton S, Brayne C, Rahkonen T, Sulkava R, Sanderson DJ, Rawlins JN, Bannerman DM, MacLullich AM and Cunningham C. Worsening cognitive impairment and neurodegenerative pathology progressively increase risk for delirium. The American journal of geriatric psychiatry: official journal of the American Association for Geriatric Psychiatry. 2015; 23(4):403-415.
137. Chu AJ, Rauci M, Nwobi OI, Mathews ST and Beydoun S. Novel anticoagulant activity of polyamino acid offsets bacterial endotoxin-induced extrinsic hypercoagulation: downregulation of monocytic tissue factor-dependent FVII activation. Journal of cardiovascular pharmacology. 2003; 42(4):477-483.
138. Chu AJ, Wang ZG, Raicu M, Beydoun S and Ramos N. Protamine inhibits tissue factor-initiated extrinsic coagulation. British journal of haematology. 2001; 115(2):392-399.
139. Slotta JE, Braun OO, Menger MD and Thorlacius H. Central role of rho kinase in lipopolysaccharide-induced platelet capture on venous endothelium. Journal of investigative medicine: the official publication of the American Federation for Clinical Research. 2008; 56(4):720-725.
140. Gorog DA and Jeong YH. Platelet function tests: why they fail to guide personalized antithrombotic medication. Journal of the American Heart Association. 2015; 4(5).
141. Yamamoto J, Inoue N, Otsui K, Ishii H and Gorog DA. Global Thrombosis Test (GTT) can detect major determinants of haemostasis including platelet reactivity, endogenous fibrinolytic and thrombin generating potential. Thrombosis research. 2014; 133(5):919-926.
142. Ghanim H, Abuaysheh S, Sia CL, Korzeniewski K, Chaudhuri A, Fernandez-Real JM and Dandona P. Increase in plasma endotoxin concentrations and the expression of Toll-like receptors and suppressor of cytokine signaling-3 in mononuclear cells after a high-fat, high-carbohydrate meal: implications for insulin resistance. Diabetes care. 2009; 32(12):2281-2287.
143. Opal SM, Scannon PJ, Vincent JL, White M, Carroll SF, Palardy JE, Parejo NA, Pribble JP and Lemke JH. Relationship between plasma levels of lipopolysaccharide (LPS) and LPS-binding protein in patients with severe sepsis and septic shock. The Journal of infectious diseases. 1999; 180(5):1584-1589.
144. Zweigner J, Gramm HJ, Singer OC, Wegscheider K and Schumann RR. High concentrations of lipopolysaccharidebinding protein in serum of patients with severe sepsis or septic shock inhibit the lipopolysaccharide response in human monocytes. Blood. 2001; 98(13):3800-3808.
145. Leante-Castellanos JL, de Guadiana-Romualdo LG, Fuentes-Gutierrez C, Hernando-Holgado A, GarciaGonzalez A and Jimenez-Santos E. The value of lipopolysaccharide binding protein for diagnosis of lateonset neonatal sepsis in very low birth weight infants. Journal of perinatal medicine. 2015; 43(2):253-257.
146. Funderburg NT, Stubblefield Park SR, Sung HC, Hardy G, Clagett B, Ignatz-Hoover J, Harding CV, Fu P, Katz JA, Lederman MM and Levine AD. Circulating CD4(+) and CD8(+) T cells are activated in inflammatory bowel disease and are associated with plasma markers of inflammation. Immunology. 2013; 140(1):87-97.
147. Broadhurst D and Kell DB. Statistical strategies for avoiding false discoveries in metabolomics and related experiments. Metabolomics. 2006; 2:171-196.
148. Leek JT and Peng RD. Statistics: P values are just the tip of the iceberg. Nature. 2015; 520(7549):612.
149. Nielsen VG, Kirklin H.K., Hoogendoorn H, Ellis T.C., Holman W.L. Thromboelastographic method to quantify the contribution of factor XIII to coagulation kinetics. Blood coagulation & Fibrinolysis: an international journal in haemostasis and thrombosis. 2007; 18(2):145-150.
150. Nielsen VG. Beyond cell based models of coagulation: analyses of coagulation with clot "lifespan" resistance-time relationships. Thrombosis research. 2008; 122(2):145-152.
151. Nielsen VG, Gurley WQ and Burch TM. The Impact of Factor XIII on Coagulation Kinetics and Clot Strength Determined by Thrombelastography. Anesthesia & Analgesia. 2004; 99(1):120-123.
152. Nielsen VG, Lyerly RT and Gurley WQ. The effect of dilution on plasma coagulation kinetics determined by thrombelastography is dependent on antithrombin activity and mode of activation. Anesthesia and analgesia. 2004; 99(6):1587-1592.
153. Haemonetics. (2011). TEG 5000 Hemostasis analyzer system. (Massachusetts: Haemonetics Corporation).
154. Nielsen VG, Audu P, Cankovic L, Lyerly RT, 3rd, Steenwyk BL, Armstead V and Powell G. Qualitative thrombelastographic detection of tissue factor in human plasma. Anesthesia and analgesia. 2007; 104(1):59-64.
155. Buys AV, Van Rooy MJ, Soma P, Van Papendorp D, Lipinski B and Pretorius E. Changes in red blood cell membrane structure in type 2 diabetes: a scanning electron and atomic force microscopy study. Cardiovascular diabetology. 2013; 12(1):25.
156. Saraf S, Christopoulos C, Salha IB, Stott DJ and Gorog DA. Impaired endogenous thrombolysis in acute coronary syndrome patients predicts cardiovascular death and nonfatal myocardial infarction. Journal of the American College of Cardiology. 2010; 55(19):2107-2115.
157. Hare DJ, Doecke JD, Faux NG, Rembach A, Volitakis I, Fowler CJ, Grimm R, Doble PA, Cherny RA, Masters CL, Bush AI and Roberts BR. Decreased plasma iron in Alzheimer's disease is due to transferrin desaturation. ACS chemical neuroscience. 2015; 6(3):398-402.
158. Brandhagen DJ, Fairbanks VF and Baldus W. Recognition and management of hereditary hemochromatosis. American family physician. 2002; 65(5):853-860.
159. Barton JC, McDonnell SM, Adams PC, Brissot P, Powell LW, Edwards CQ, Cook JD and Kowdley KV. Management of hemochromatosis. Hemochromatosis Management Working Group. Annals of internal medicine. 1998; 129(11):932-939.
160. Bester J, Buys AV, Lipinski B, Kell DB and Pretorius E. High ferritin levels have major effects on the morphology of erythrocytes in Alzheimer's disease. Frontiers in aging neuroscience. 2013; doi: 10.3389/fnagi.2013.00088. eCollection 2013.
161. Ritchie RF, Palomaki GE, Neveux LM, Navolotskaia O, Ledue TB and Craig WY. Reference distributions for the negative acute-phase serum proteins, albumin, transferrin and transthyretin: a practical, simple and clinically relevant approach in a large cohort. Journal of clinical laboratory analysis. 1999; 13(6):273-279.
162. Giometto B, Argentiero V, Sanson F, Ongaro G and Tavolato B. Acute-phase proteins in Alzheimer's disease. European neurology. 1988; 28(1):30-33.
163. Pretorius E, Swanepoel AC, Buys AV, Vermeulen N, Duim W and Kell DB. Eryptosis as a marker of Parkinson's disease. Aging-US. 2014; 6:788-818.
164. Pretorius E, Vermeulen N, Bester J, du Plooy JL and Gericke GS. The effect of iron overload on red blood cell morphology. The Lancet. 2014; 383:722.
165. Pretorius E. The adaptability of red blood cells. Cardiovascular diabetology. 2013; 12:63.
166. van Rooy M and Pretorius E. Metabolic syndrome, platelet activation and the development of transient ischemic attack or thromboembolic stroke. Thrombosis research. 2015; 135(3):434-442.
167. Lang F and Qadri SM. Mechanisms and significance of eryptosis, the suicidal death of erythrocytes. Blood purification. 2012; 33(1-3):125-130.
168. Lang E, Qadri SM and Lang F. Killing me softly-suicidal erythrocyte death. The international journal of biochemistry & cell biology. 2012; 44(8):1236-1243.
169. Qadri SM, Kucherenko Y, Zelenak C, Jilani K, Lang E and Lang F. Dicoumarol activates Ca2+-permeable cation channels triggering erythrocyte cell membrane scrambling. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology. 2011; 28(5):857-864.
170. Qadri SM, Bauer J, Zelenak C, Mahmud H, Kucherenko Y, Lee SH, Ferlinz K and Lang F. Sphingosine but not sphingosine-1-phosphate stimulates suicidal erythrocyte death. Cellular physiology and biochemistry: international journal of experimental cellular physiology, biochemistry, and pharmacology. 2011; 28(2):339-346.
171. Pretorius E, Oberholzer HM, van der Spuy WJ, Swanepoel AC and Soma P. Qualitative scanning electron microscopy analysis of fibrin networks and platelet abnormalities in diabetes. Blood coagulation & fibrinolysis: an international journal in haemostasis and thrombosis. 2011; 22(6):463-467.
172. Van Der Spuy WJ and Pretorius E. A place for ultrastructural analysis of platelets in cerebral ischemic research. Microsc Res Tech. 2013; 76(8):795-802.
173. Ai Q, Jing Y, Jiang R, Lin L, Dai J, Che Q, Zhou D, Jia M, Wan J and Zhang L. Rotenone, a mitochondrial respiratory complex I inhibitor, ameliorates lipopolysaccharide/Dgalactosamine-induced fulminant hepatitis in mice. International immunopharmacology. 2014; 21(1):200-207.
174. Alpsoy S, Akyuz A, Erfan G, Akkoyun DC, Topcu B, Guzel S, Kaya S and Kulac M. Atherosclerosis, some serum inflammatory markers in psoriasis. Giornale italiano di dermatologia e venereologia: organo ufficiale, Societa italiana di dermatologia e sifilografia. 2014; 149(2):167-175.
175. Amar J, Lange C, Payros G, Garret C, Chabo C, Lantieri O, Courtney M, Marre M, Charles MA, Balkau B, Burcelin R and Group DESIRS. Blood microbiota dysbiosis is associated with the onset of cardiovascular events in a large general population: the D.E.S.I.R. study. PLoS One. 2013; 8(1):e54461.
176. Aksu G, Ozturk C, Kavakli K, Genel F and Kutukculer N. Hypercoagulability: interaction between inflammation and coagulation in familial Mediterranean fever. Clinical rheumatology. 2007; 26(3):366-370.
177. Anžej S, Božic M, Antovic A, Peternel P, Gašperšic N, Rot U, Tratar G and Stegnar M. Evidence of hypercoagulability and inflammation in young patients long after acute cerebral ischaemia. Thrombosis research. 2007; 120(1):39-46.
178. Arshad F, Lisman T and Porte RJ. Hypercoagulability as a contributor to thrombotic complications in the liver transplant recipient. Liver international: official journal of the International Association for the Study of the Liver. 2013; 33(6):820-827.
179. Choi G, Schultz MJ, Levi M and van der Poll T. The relationship between inflammation and the coagulation system. Swiss Med Wkly. 2006; 136(9-10):139-144.
180. Cicala C and Cirino G. Linkage between inflammation and coagulation: an update on the molecular basis of the crosstalk. Life sciences. 1998; 62(20):1817-1824.
181. Conway EM. Thrombomodulin and its role in inflammation. Semin Immunopathol. 2012; 34(1):107-125.
182. Emsley HC and Tyrrell PJ. Inflammation and infection in clinical stroke. Journal of cerebral blood flow and metabolism: official journal of the International Society of Cerebral Blood Flow and Metabolism. 2002; 22(12):1399-1419.
183. Esmon CT. The interactions between inflammation and coagulation. British journal of haematology. 2005; 131(4):417-430.
184. Koch L, Hofer S, Weigand MA, Frommhold D and Poeschl J. Lipopolysaccharide-induced activation of coagulation in neonatal cord and adult blood monitored by thrombelastography. Thrombosis research. 2009; 124(4):463-467.